Retatrutide
About
About Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the most mechanistically advanced anti-obesity peptide in late-stage clinical development. Phase II trials reported mean body weight reductions of 24% over 48 weeks — the largest pharmacological weight loss ever recorded in a randomized controlled trial. It is being developed by Eli Lilly and is expected to enter Phase III trials in 2025–2026.
Science
Mechanism of Action
Simultaneously activates GLP-1 receptors (appetite suppression, insulin secretion), GIP receptors (enhanced insulin response, adipocyte signaling), and glucagon receptors (increased energy expenditure and hepatic glucose regulation), producing synergistic metabolic effects beyond dual agonists.
Dosing
Typical Protocol
Phase II doses ranged from 1–12 mg subcutaneous injection once weekly; not yet commercially available.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Retatrutide — with trust scores, legal credentials, and pricing transparency.